Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM THIOSULFATE vs JOENJA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium thiosulfate acts as a cyanide antidote by providing a sulfur donor for the enzyme rhodanese, which converts cyanide to the less toxic thiocyanate. It also acts as a reducing agent and chelator of calcium, forming soluble calcium thiosulfate complexes.
JOENJA (lenvatinib) is a tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. It blocks tumor angiogenesis and proliferation.
FDA-approved: Acute cyanide poisoning (in combination with sodium nitrite),Off-label: Reduction of nephrotoxicity from cisplatin chemotherapy,Off-label: Calciphylaxis (calcium uremic arteriolopathy),Off-label: Treatment of extravasation of vesicant drugs
Differentiated thyroid cancer (DTC) refractory to radioactive iodine,Renal cell carcinoma (RCC) in combination with everolimus,Hepatocellular carcinoma (HCC) first-line treatment in combination with pembrolizumab
12.5 g (50 m L of 25% solution) intravenously over 10 minutes for cyanide poisoning; for cisplatin otoprotection: 9 g/m² intravenously over 15 minutes after cisplatin.
JOENJA (lenalidomide) 2.5 mg orally once daily on days 1-21 of a 28-day cycle.
Terminal elimination half-life: 0.65 hours (IV in cyanide poisoning); context: rapid redistribution and excretion, requiring repeated doses.
Terminal elimination half-life is approximately 12-15 hours in patients with normal renal function. This supports once-daily dosing in most indications. Half-life is prolonged in renal impairment, requiring dose adjustment.
Sodium thiosulfate is metabolized via the enzyme rhodanese (in liver and other tissues) to thiocyanate, which is then excreted renally. It also undergoes oxidation to sulfate.
Primarily metabolized by CYP3A4 and aldehyde oxidase (AO). Minor pathways include CYP3A5 and CYP2C8.
Renal: >90% unchanged; minor biliary/fecal.
Primarily renal excretion of unchanged drug (approximately 70-80% of the dose). A small fraction (5-10%) is eliminated via feces via biliary excretion. The remainder is metabolized and excreted as inactive metabolites.
<5%; primarily albumin.
Approximately 90-95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. Binding is saturable at high concentrations and may be altered in disease states (e.g., hepatic impairment, hypoalbuminemia).
0.2-0.3 L/kg; indicates primarily extracellular distribution.
Volume of distribution is approximately 0.6-0.8 L/kg, indicating distribution into total body water. This suggests extensive extravascular distribution, with higher concentrations in well-perfused organs (liver, kidneys) and lower in adipose tissue.
Oral: approximately 0% (poorly absorbed, degraded in stomach); IV: 100%.
Oral bioavailability is approximately 60-70%, with moderate interindividual variability. Food does not significantly affect absorption. No other relevant routes (e.g., topical) are available; bioavailability via IV is 100%.
No dose adjustment required for GFR >30 m L/min; for GFR ≤30 m L/min, consider reducing dose by 50% or extending interval to every 12 hours due to possible thiosulfate accumulation.
For Cr Cl 30-60 m L/min: 2.5 mg orally once daily; for Cr Cl <30 m L/min (not on dialysis): 1.25 mg orally once daily; for ESRD on dialysis: 2.5 mg orally once daily, dose after dialysis.
No specific recommendations for Child-Pugh; use with caution in severe hepatic impairment due to potential metabolic and elimination effects.
No dose adjustment required for mild to moderate hepatic impairment; not studied in severe impairment (Child-Pugh C).
For cyanide poisoning: 412.5 mg/kg (1.65 m L/kg of 25% solution) intravenously over 10 minutes; for methemoglobinemia: 1 mg/kg intravenously over 10 minutes.
Safety and efficacy not established in pediatric patients under 18 years.
No specific dose adjustments; monitor renal function and volume status due to sodium load and potential reduced clearance.
No specific dose adjustment; monitor renal function and adjust dose based on Cr Cl.
None.
None.
Hypotension and increased anion gap metabolic acidosis (especially with high doses or rapid infusion),Hypocalcemia due to calcium chelation; monitor calcium levels,Thiocyanate accumulation, particularly in renal impairment; can lead to toxicity (e.g., nausea, disorientation, psychosis, muscle cramps),Hydration status should be monitored to avoid volume overload,Hypersensitivity reactions may occur
Hypertension (including hypertensive crisis),Cardiac dysfunction (reduced LVEF),Arterial thromboembolic events,Hepatic impairment (including hepatotoxicity),Renal impairment (including proteinuria),Hemorrhage,Gastrointestinal perforation or fistula,QT prolongation,Reversible posterior leukoencephalopathy syndrome (RPLS),Thyroid dysfunction,Wound healing complications
Known hypersensitivity to sodium thiosulfate or any component,Relative: Severe renal impairment (risk of thiocyanate toxicity)
None known
No known food interactions. Maintain adequate hydration unless contraindicated by renal status.
Avoid grapefruit, grapefruit juice, and star fruit as they inhibit CYP3A4 and may increase lapatinib levels. Administer on an empty stomach; food, especially high-fat meals, can increase lapatinib AUC by 2-3 times and Cmax by 3-4 times, increasing toxicity risk.
Sodium thiosulfate is not known to be teratogenic. No specific fetal risks have been identified; however, data in pregnant women are limited. It is used as an antidote for cyanide poisoning during pregnancy when benefit outweighs risk.
First trimester: Based on animal studies, there is evidence of teratogenicity including cardiovascular and neural tube defects. Human data are limited; however, the drug should be avoided in the first trimester unless benefits outweigh risks. Second/third trimester: May cause fetal growth restriction and oligohydramnios; use only if clearly needed.
Sodium thiosulfate is excreted into breast milk in small amounts; M/P ratio is not established. It is considered compatible with breastfeeding, but caution is advised due to limited data.
Unknown if excreted in human milk. The M/P ratio has not been determined. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for at least 1 month after last dose.
No dosage adjustment is recommended for pregnancy. Pharmacokinetic changes in pregnancy are not well studied; standard weight-based dosing for cyanide poisoning should be used.
Due to increased plasma volume and renal clearance during pregnancy, higher doses may be required. Consider dose titration based on therapeutic drug monitoring and clinical response. No specific dose adjustment is established; individualize therapy.
Sodium thiosulfate is used as an antidote for cyanide poisoning and for calciphylaxis. In cyanide poisoning, administer IV with sodium nitrite; monitor for hypotension and methemoglobinemia. For calciphylaxis, use after hemodialysis to prevent hypernatremia. Can cause prolonged QT interval, so monitor ECG. Do not mix with other drugs in IV line; incompatible with cisplatin.
JOENJA (lapatinib) is a dual tyrosine kinase inhibitor of EGFR and HER2. Use with caution in patients with severe hepatic impairment (Child-Pugh C); reduce dose to 750 mg/day. Monitor for QT prolongation, especially in patients with hypokalemia or hypomagnesemia, or those on concurrent QT-prolonging drugs. Diarrhea is common (grades 1-2 in ~50%); premedicate with loperamide and ensure adequate hydration. Hepatotoxicity (ALT >5x ULN) occurs in ~2%; discontinue if severe. Avoid concurrent strong CYP3A4 inducers (e.g., rifampin) as they decrease lapatinib AUC by up to 70%.
This medication is given intravenously to treat cyanide poisoning or a skin condition called calciphylaxis.,You may experience side effects such as nausea, vomiting, headache, or a metallic taste.,Your blood pressure, heart rhythm, and blood levels will be monitored during treatment.,Tell your doctor if you have heart problems, kidney disease, or low sodium levels.,Do not drink alcohol while on this medication.
Take JOENJA on an empty stomach, at least 1 hour before or 1 hour after a meal; do not take with food as it increases absorption unpredictably.,Do not crush, chew, or split tablets; swallow whole.,If you miss a dose, take it as soon as you remember unless it is less than 12 hours before the next dose; then skip the missed dose.,Avoid grapefruit, grapefruit juice, and star fruit during treatment.,Use effective non-hormonal contraception during treatment and for at least 1 week after the last dose.,Report severe or persistent diarrhea, yellowing of skin or eyes, dark urine, or unusual bruising/bleeding to your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM THIOSULFATE vs JOENJA, answered by our medical review team.
SODIUM THIOSULFATE is a Cyanide Antidote that works by Sodium thiosulfate acts as a cyanide antidote by providing a sulfur donor for the enzyme rhodanese, which converts cyanide to the less toxic thiocyanate. It also acts as a reducing agent and chelator of calcium, forming soluble calcium thiosulfate complexes.. JOENJA is a Sphingosine 1-Phosphate Receptor Modulator that works by JOENJA (lenvatinib) is a tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. It blocks tumor angiogenesis and proliferation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM THIOSULFATE and JOENJA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM THIOSULFATE is: 12.5 g (50 m L of 25% solution) intravenously over 10 minutes for cyanide poisoning; for cisplatin otoprotection: 9 g/m² intravenously over 15 minutes after cisplatin.. The standard adult dose of JOENJA is: JOENJA (lenalidomide) 2.5 mg orally once daily on days 1-21 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM THIOSULFATE and JOENJA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM THIOSULFATE is classified as Category C. Sodium thiosulfate is not known to be teratogenic. No specific fetal risks have been identified; however, data in pregnant women are limited. It is used as an antidote for cyanide . JOENJA is classified as Category C. First trimester: Based on animal studies, there is evidence of teratogenicity including cardiovascular and neural tube defects. Human data are limited; however, the drug should be . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.